Industry: Cannabis Biotech

Cannabis biotech funding

Investors in cannabinoid medicine pay for controlled trial data and a drug that can get through FDA review and DEA rules. Waveup turns your science, regulatory plan and likely buyers into a case they can test.

  • Investor lists and market data on cannabinoid medicines
  • Decks and models built on trial readouts, DEA steps and licensing
  • Waveup prepares investor materials for cannabis biotech companies: $3B+ raised for 600+ startups since 2014

In short

What is cannabis biotech funding?

Cannabis biotech funding is money raised by companies turning cannabinoids into prescription drugs. The molecules are extracted from the plant, made by chemical synthesis or brewed by engineered microbes. The money comes from life sciences VCs, research grants and drugmakers that license or buy drugs. The field's one plant-derived approved drug, Epidiolex, passed $1 billion in sales in 2025.

Who it's for
Cannabinoid drug developers and makers of synthetic or biosynthetic cannabinoids, pre-seed to Series D+
What we build
Investor deck, financial model, valuation, investor list, data room
Track record
$3B+ raised for 600+ startups since 2014

Market data checked on 6 November 2026. Sources are under each section.

Do investors still back cannabinoid drugs in 2026?

Yes, when a developer has controlled trial data and a clear route through the FDA. Recent trial misses have made investors stricter about both.

The opportunity

Approved cannabinoid drugs sell, and US research rules are easing.

  • Drugmakers have bought cannabinoid developers, from Epidiolex's maker to a CB1 blocker startup
  • A 2026 DEA rule lets registered researchers use products from state-licensed sources
  • Drugs aimed at the body's own cannabinoid system have reached Phase 2, such as Synendos's anxiety candidate

The problem

Late-stage trials can still fail. Harmony's Phase 3 study of a CBD gel in 215 patients missed its main goal in September 2025.

Market size

How big is the market for cannabinoid medicines?

Epidiolex, the only FDA-approved drug derived from cannabis, had net sales of $1.06B in 2025. These four trends set the terms for newcomers:

  • Steady demand: Epidiolex net sales reached $837M in the first nine months of 2026, up on a year earlier
  • New forms: the FDA's target date for a decision on Jazz's cannabidiol capsule is 16 April 2027
  • Rescheduling: since 28 April 2026, marijuana in an FDA-approved drug sits in Schedule III, not Schedule I
  • Research policy: a December 2025 executive order calls for more medical marijuana and CBD research
Epidiolex net sales: $275.0M in Q4 2024, $217.7M in Q1 2025 and $295.4M in Q3 2026.

Cannabis biotech in 2026, in six numbers

4

cannabinoid drugs approved by the FDA: Epidiolex from the plant, plus three synthetic ones

$500M+

of Epidiolex net sales in 2020, before Jazz bought its maker, GW Pharmaceuticals

~25%

of Jazz's 2025 revenue came from Epidiolex, by our arithmetic

542

studies on ClinicalTrials.gov list cannabidiol as an intervention (November 2026)

101

of those cannabidiol studies are Phase 3 or combined Phase 2/3

87

cannabidiol studies were recruiting patients in November 2026

Venture capital

Who pays for cannabinoid drug development now?

Venture totals for cannabinoid drug developers aren't published anywhere we could find, so the chart tracks NIH research money. Private rounds are rare, and drugmakers tend to step in once a drug has human data.

NIH funding for cannabinoid research: $115M in fiscal 2016, $238M in 2023 and $233M in 2025.
$7.2B

total price Jazz agreed in 2021 for GW Pharmaceuticals, the maker of Epidiolex

Up to $1.075B

agreed by Novo Nordisk in 2023 for Inversago, a CB1 blocker developer, tied to milestones

CHF 20M

Series A for Synendos in 2020, co-led by Kurma Partners and Sunstone Life Science Ventures

Who invests in cannabis biotech startups?

Life sciences VCs that backed a cannabinoid drug developer, drugmakers that bought cannabinoid medicines, and US research money. For more biotech investors, see our life sciences VC list.

Investor
Type and base
Cannabinoid companies backed
Stage or cheque
Kurma Partners
Healthcare and biotech VC, Paris
Synendos Therapeutics; also Pharvaris and Zealand Pharma
Company creation to capital expansion; €1B managed
Ysios Capital
Life sciences VC, Barcelona and San Sebastián
Synendos; also Neurona Therapeutics (bought by UCB) and Minoryx
Not stated; new €100M fund for biotech company creation (2026)
Jazz Pharmaceuticals
Biopharma company, Dublin
GW Pharmaceuticals, bought in 2021 with Epidiolex
Acquisitions
CNX Therapeutics
European specialty pharma, London
Sativex, bought from Jazz in 2025; also Latuda and Loxapac
Acquires specialty medicines in CNS and critical care
NIH
US federal medical research agency
Projects in its Cannabinoid Research category
Research funding; $233M in fiscal 2025

Investor database

Biotech investors in our database

The funds with the most biotech investments. Pick a stage, or open a fund for its cheque sizes.

Top 5 by biotech investments

  • Investments by industry

    • Healthtech & Wellness47%
    • Biotech26%
    • Pharma20%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    $100K–$500K$500K–$1M$1M–$3M$3M–$10M
    Based in
    Chicago, United States
    Invests in
    USA

    502 investments in total, 23 tagged Biotech.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness41%
    • Biotech36%
    • Pharma18%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
    Based in
    Boston, United States
    Invests in
    USA

    141 investments in total, 22 tagged Biotech.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness38%
    • Biotech33%
    • Pharma17%
    Rounds
    SeedSeries ASeries C+
    Average cheque
    $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
    Based in
    San Francisco, United States
    Invests in
    USA

    196 investments in total, 20 tagged Biotech.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness44%
    • Biotech27%
    • Pharma15%
    Rounds
    Series ASeries BSeries C+
    Average cheque
    Not listed
    Based in
    Boston, United States

    439 investments in total, 18 tagged Biotech.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness46%
    • Biotech25%
    • Pharma16%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    Not listed
    Based in
    United States
    Invests in
    Israel, Europe, USA +1

    231 investments in total, 17 tagged Biotech.Open the full fund profile

From our investor database.

What makes cannabinoid drug developers hard to fund?

In our Fundraising 2025 study, 56 VCs named their top reasons to pass. Revenue growth, unit economics, burn and missed milestones came first, then defensibility and crowded categories. In cannabinoid medicine, the missed milestone is usually a trial, and defensibility means what you can patent.

Trials that miss

Skye's CB1 antibody missed its main goal when given alone in a 2025 trial. Skye paused the drug in Q2 2026 and agreed to combine with Redx, a UK fibrosis drug developer.

What investors ask

  • How does your drug do next to what patients already take?

What your deck shows

  • Trials that test your drug on top of, or against, current care
  • Cash for a second trial if the first one misses

Two regulators, one timeline

A US trial can start 30 days after an IND filing unless the FDA acts sooner. Studies of Schedule I drugs also need a DEA registration for each site.

What investors ask

  • Which DEA steps sit between your IND and the first patient dosed?

What your deck shows

  • FDA and DEA steps on one dated timeline
  • A licensed source of research-grade drug

Data you can file

Universities and hospitals run much of the research. Only 190 of the 542 cannabidiol studies on ClinicalTrials.gov list industry as a funder.

What investors ask

  • Which of your results come from controlled trials you can submit to the FDA?

What your deck shows

  • Your own controlled data, set apart from academic studies
  • Data rights agreed with every academic partner

Plant, synthetic or brewed

The DEA's April 2026 rule moved marijuana in FDA-approved drugs into Schedule III. Synthetic THC stayed in Schedule I under the same rule.

What investors ask

  • Which schedule covers your molecule, before and after approval?

What your deck shows

  • Counsel's view of your molecule's legal status
  • A supply chain that stays compliant if rules change

How we help you raise

Flat fees agreed before we start. No success fee on advisory work.

Who we are

Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups. Biotech and pharma are the largest group among our 54+ deep-tech projects.

About us
Track record
$3B+
raised for 600+ startups
Decks
1,000+
decks since 2014
M&A
50+
M&A transactions supported, including 20+ exits
Health
11%
of our projects on record are in healthcare and life sciences

Cannabis biotech funding FAQ

What does a cannabis biotech company do?
It turns cannabinoids into prescription drugs and tests them in clinical trials for approval. Some extract the molecule from the plant, as GW did for Epidiolex. Others make it by chemical synthesis or in engineered yeast, or design new molecules for the body's cannabinoid receptors. A few licensed growers also call themselves biotechs, but they sell cannabis, not approved drugs. Growers are covered on our cannabis page.
Which cannabinoid drugs has the FDA approved?
How do cannabis biotech startups get funding?
What do investors look for in a cannabinoid drug developer?
Is cannabis research getting easier in the US?
How much does help with a cannabis biotech raise cost?

Raising for a cannabis biotech company?

Share your molecule, how you make it and your next trial readout. We'll show you how a life sciences investor is likely to read your case.

Have a project in mind?

Leave your information below and one of our experts will be in touch to schedule a call.

Your name:
*Your email:
*You need help with:
Your project is:
Your current stage:
Your maximum budget:
How did you find us?